Chronic pain remains a major public health issue today, as it is often difficult to treat. Research into and the development of new pain-relieving medicines are therefore essential.
Serotonergic receptors (serotonin receptors, 5-HT), located on the surface of neurons, are targets of several classes of drugs, including antidepressants, antiemetics, antipsychotics, antimigraine medications, appetite suppressants, and psychoactive substances. They therefore play an important role in numerous physiological and behavioral processes. Among them, the 5-HT7 receptor, which belongs to the G protein-coupled receptor (GPCR) superfamily, plays a key role in pain modulation.
In 2022, researchers from the University of Orléans discovered that a new molecule, Serodolin, specifically activates the 5-HT7 receptor through a novel mechanism, acting as the first β-arrestin pathway biased agonist. This activation produces a therapeutic effect whose efficacy is comparable to that of morphine in several preclinical models.
To further support the development of this drug candidate, the authors of this study used positron emission tomography (PET) to assess in vivo, in healthy rodents, the ability of Serodolin to cross the blood–brain barrier and bind specifically in the brain. PET is indeed a gold-standard molecular imaging technique for real-time quantification of a molecule's distribution and for obtaining detailed information on the metabolic pathways involved.
Serodolin was labeled with carbon-11 without any change to its chemical structure. Automated radiosynthesis yielded [¹¹C] Serodolin with a radiochemical yield of 79% in 30 min. Quality control showed that [¹¹C] Serodolin had a radiochemical and chemical purity of over 95%. PET brain imaging and kinetic analysis in healthy rats revealed rapid accumulation of radiolabeled Serodolin, as well as widespread distribution throughout the brain parenchyma. Furthermore, co-injection with non-radioactive Serodolin resulted in a generalized and significant reduction in brain exposure, demonstrating specific binding of the compound.
These findings demonstrate central target engagement by Serodolin and support further development of this molecule as a potential antinociceptive drug.
Joliot institute contacts: Fabien Caillé (fabien.caille@cea.fr); Davide Audisio (davide.audisio@cea.fr)
- Serodoline (often spelled Serodolin in the scientific literature) is an antinociceptive drug candidate known as a β-arrestin pathway-biased ligand of the serotonin 5-HT₇ receptor.
- A biased agonist (or functionally selective agonist) is a molecule that binds to a cell-surface receptor (often a G protein-coupled receptor, GPCR) and preferentially activates one signaling pathway over the other pathways that the receptor can trigger.
- The β-arrestin pathway is a cellular regulatory and signaling pathway associated with GPCRs. Its activation induces biological responses to a wide range of extracellular signals.